Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
WTO agreement: The fine print - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Sep 2, 2003

    WTO agreement: The fine print

    Indian pharma stocks are having a dream run on the bourses in the past few weeks. Many companies like Cipla, Ranbaxy, Nicholas Piramal, Wockhardt, Aurobindo Pharma and Kopran are trading at their 52-week high levels. One of the major reasons for this upswing that is doing the rounds is the fact that the WTO members have finally agreed on a draft resolution regarding the licensing of life-saving drugs to least developed countries and its possible upside for the Indian companies. In this article, we shall study the impact of the WTO draft agreement on the Indian companies and thus find out how justified the above reason is.

    A brief history...
    WTO resolution on TRIPS provides that a product patents regime will have to be implemented in a phased manner in 2005 in developing countries and from 2015 in the least developed countries. Thus, companies will not be allowed to make generics version of the patented drugs and market the same. The patent holder will be provided with complete patent protection and will launch its patented drugs in the developing markets. However, the drug prices will increase manifolds resulting in it being inaccessible to most in the poor countries. Hence, there was a need to amend the regulation and insert a clause, which could allow the poorer nations to breach the patent regulation during an emergency.

    In the Doha round, all the WTO members had drawn up a draft agreement that allowed least developed countries, in case of national emergencies, to waive the patent on the drugs required enabling it to import the drug from generics manufacturers. This would have ensured the availability of drugs at low prices. However, the powerful US pharma lobby ensured that US blocked the draft agreement.

    US concerns...
    The primary concern that US had was a blanket waiver on patents might result in the generics companies getting a right to manufacture non-essential drugs (like Viagra) as well. Moreover, they also feared that the generics drugs thus manufactured might get exported to the developed markets thereby affecting the revenues of the patent holder. Consequently there was a need to hold further discussions before the Cancun round began.

    Deadlock broken...
    Just before the Cancun ministerial conference, representatives from USA, India, Brazil, South Africa and Kenya finally succeeded in breaking the ice. According to the new draft agreement, if there is a health emergency arising in a country with inadequate drug manufacturing facility, they can license a company from another country to manufacture a generics version of the patented drug required to satisfy the health requirements. The poorer nations will thus be better equipped to face a health catastrophe.

    Impact on Indian companies...
    The new draft resolution, although a positive for mankind as a whole, is not all smiles for the Indian companies. First the positives.

    The agreement gives the Indian companies a legitimate right to sell generics version of patented drugs in poor countries. India being one of the most cost effective manufacturers of drugs will be the favored supplier of the drugs for these countries. The fact that India has US FDA approved manufacturing facilities is an added advantage. Thus companies like Cipla, Aurobindo Pharma, Lupin and some of the other mid-cap companies with good manufacturing facilities might find these opportunities as a growth driver.

    Now for the downside. Although the agreement does give the Indian companies a right to sell the drugs to these developing countries, it is going to be a low margin business. This is primarily because the drugs are required to be provided at a very low price. Moreover, the new draft agreement requires that the drug supplied under this provision should be clearly identifiable and have a different packing, colour or shape as compared to the patented drug. This could push the costs up and put further pressure on the margins thereby making the supply unviable. Moreover, there are many procedural constraints, which make the export cumbersome. The company will also have to negotiate the royalty payable to the patent holder on behalf of the importing country. Further, there is little protection to the supplying company in case the patent holder files any patent infringement suit. Finally, the license will be issued only for killer diseases like AIDS, malaria and tuberculosis thereby restricting the segments open to the Indian companies.

    In a nutshell...
    Although the Indian companies are to gain from the WTO agreement, the gain is miniscule. Since the margins are expected to be very low, the profits generated might not be high enough to change the fortunes of large companies like Cipla, Ranbaxy, Dr Reddy's, etc. Indian companies have more remunerative opportunities in the post 2005 era, which would decide the fate of the companies in the long run. Thus, although the WTO agreement is a big break through for humanity, Indian companies as such are not likely to benefit from the same in a big way. Thus, though a stock market upswing in the pharma sector is justified in view of the tremendous growth potential that Indian pharma companies hold, a surge in the prices on the back of the WTO agreement does raise doubts. So, be careful while investing.



    Equitymaster requests your view! Post a comment on "WTO agreement: The fine print". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 09:42 AM